Sanofi Consumer Healthcare India (NSE:SANOFICONR) Research & Development: ₹0 Mil (TTM As of Mar. 2026)


NSE:SANOFICONR Sanofi Consumer Healthcare India Ltd NSE:SANOFICONR
21 GF Score
Price ₹4,607.60
! 2 Warning Signs
View Full Analysis

What is Sanofi Consumer Healthcare India Research & Development?

Sanofi Consumer Healthcare India NSE:SANOFICONR -0.24% 21 Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:SANOFICONR with a GF Score™ of 21/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Sanofi Consumer Healthcare India's Research & Development for the three months ended in Mar. 2026 was ₹0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

Sanofi Consumer Healthcare India  (NSE:SANOFICONR) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Sanofi Consumer Healthcare India Research & Development Related Terms

Sanofi Consumer Healthcare India Research & Development Historical Data

* Premium members only.

The historical data trend for Sanofi Consumer Healthcare India's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sanofi Consumer Healthcare India Research & Development Chart

Sanofi Consumer Healthcare India Annual Data
Trend Dec23 Dec24 Dec25
Research & Development
0.00 0.00 0.00

Sanofi Consumer Healthcare India Quarterly Data
Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:SANOFICONR
21GF Score
Sanofi Consumer Healthcare India Ltd NSE:SANOFICONR
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sanofi Consumer Healthcare India Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0 Mil mean?
Sanofi Consumer Healthcare India (NSE:SANOFICONR) has a Research & Development of ₹0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Sanofi Consumer Healthcare India and its competitors.
Is Sanofi Consumer Healthcare India's Research & Development too high?
Sanofi Consumer Healthcare India's current Research & Development is ₹0 Mil. Overall, Sanofi Consumer Healthcare India has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Sanofi Consumer Healthcare India's Research & Development compare to LLY and JNJ?
Sanofi Consumer Healthcare India's Research & Development of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Sanofi Consumer Healthcare India and its competitors. Sanofi Consumer Healthcare India's current Research & Development is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi Consumer Healthcare India stock overvalued right now?
Sanofi Consumer Healthcare India (NSE:SANOFICONR) has a current Research & Development of ₹0 Mil. The current Research & Development is ₹0 Mil. Sanofi Consumer Healthcare India's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Sanofi Consumer Healthcare India (NSE:SANOFICONR), the current Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sanofi Consumer Healthcare India Business Description

Other Exchanges 544250:India
Address Pirojshanagar, Eastern Express Highway, Unit 1104, 11th Floor, Godrej Two, Vikhroli East, Mumbai, MH, IND, 400079
Sanofi Consumer Healthcare India Ltd is mainly engaged in the business of manufacturing and trading of drugs and pharmaceutical products. The Company also has various independent contract/third-party manufacturers based across the country and provides business support services to its group entity in India. Its products include Allergy Relief (Allegra), Pain Care (Combiflam), and Physical Wellness (DePURA). The Company sells its products in India through independent distributors and outside India. Its operations are limited to one segment, namely Pharmaceutical Business. The Company operates in India, which generates the maximum revenue, and Outside India.
21GF Score

Get the complete analysis for NSE:SANOFICONR

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹4,607.60
Price